Skip to Main Content

Paper Details

Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.
Nature
132
2022
Author NameAffiliation
Rahul K SuryawanshiGladstone Institutes
Camille R SimoneauGladstone Institutes
Camille R SimoneauUniversity of California san francisco
Camille R SimoneauQuantitative Biosciences Institute COVID-19 Research Group, University of California san francisco
Mir M KhalidGladstone Institutes
Gaurav KumarGladstone Institutes
Mauricio MontanoGladstone Institutes
Mauricio MontanoMichael Hulton Center for HIV Cure Research at Gladstone
Chia-Lin TsouGladstone Institutes
Frank W SovegGladstone Institutes
Michael A MatthayCardiovascular Research Institute, University of California san francisco
Michael A MatthayCardiovascular Research Institute, University of California san francisco
Warner C GreeneGladstone Institutes
Warner C GreeneUniversity of California san francisco
Warner C GreeneMichael Hulton Center for HIV Cure Research at Gladstone
Warner C GreeneUniversity of California san francisco
Raul AndinoUniversity of California san francisco
Nadia R RoanGladstone Institutes
Nadia R RoanUniversity of California san francisco
Jennifer A DoudnaGladstone Institutes
Jennifer A DoudnaInnovative Genomics Institute, University of California berkeley
Jennifer A DoudnaUniversity of California berkeley
Jennifer A DoudnaLawrence Berkeley National Laboratory
Jennifer A DoudnaHoward Hughes Medical Institute, University of California berkeley
Jennifer A DoudnaUniversity of California berkeley
Jennifer A DoudnaCalifornia Institute for Quantitative Biosciences, University of California berkeley
Melanie OttGladstone Institutes
Melanie OttUniversity of California san francisco
Melanie OttQuantitative Biosciences Institute COVID-19 Research Group, University of California san francisco
Melanie Ott
  • 1 - 30

Datasets

Release 1.2